Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

INSM – Insmed Incorporated

Float Short %

4.61

Margin Of Safety %

Put/Call OI Ratio

1.11

EPS Next Q Diff

0.5

EPS Last/This Y

0.06

EPS This/Next Y

1.7

Price

131.85

Target Price

147.82

Analyst Recom

1.15

Performance Q

99.33

Relative Volume

0.54

Beta

0.94

Ticker: INSM




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25INSM103.950.940.5980239
2025-07-28INSM101.880.943.9580861
2025-07-29INSM104.851.081.0187316
2025-07-30INSM105.071.070.1488279
2025-07-31INSM107.321.070.0488889
2025-08-01INSM108.71.030.4590743
2025-08-04INSM111.281.020.4592351
2025-08-05INSM111.61.010.8894097
2025-08-06INSM111.321.021.3094508
2025-08-07INSM109.361.060.2295529
2025-08-08INSM109.571.030.1197517
2025-08-11INSM112.921.010.9398546
2025-08-12INSM122.011.020.22101951
2025-08-13INSM122.891.010.47103421
2025-08-14INSM127.771.020.21103097
2025-08-15INSM127.61.031.25107949
2025-08-18INSM127.381.130.3760788
2025-08-19INSM127.271.131.8361680
2025-08-20INSM129.351.180.1363230
2025-08-21INSM132.621.120.4465952
2025-08-22INSM131.881.110.3068180
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25INSM103.9532.39.0-5.19
2025-07-28INSM101.8632.331.3-5.19
2025-07-29INSM105.0032.3-16.5-5.19
2025-07-30INSM105.1832.311.4-5.19
2025-07-31INSM107.2832.3-5.5-5.19
2025-08-01INSM108.6932.31.2-5.19
2025-08-04INSM111.2432.4-8.7-5.19
2025-08-05INSM111.6132.49.8-5.19
2025-08-06INSM111.2632.415.7-5.19
2025-08-07INSM109.3032.429.0-5.19
2025-08-08INSM109.5532.410.7-5.19
2025-08-11INSM112.9132.44.3-5.19
2025-08-12INSM121.97-9.5-148.2-5.51
2025-08-13INSM122.87-9.8-70.1-5.51
2025-08-14INSM127.84-9.8-105.6-5.53
2025-08-15INSM127.86-10.1-57.1-5.55
2025-08-18INSM127.39-10.1-52.8-5.55
2025-08-19INSM127.21-10.1-55.7-5.55
2025-08-20INSM129.42-10.1-74.6-5.55
2025-08-21INSM132.61-8.6-82.0-5.51
2025-08-22INSM131.85-8.6-50.3-5.51
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25INSM-23.554.995.22
2025-07-28INSM-23.550.905.22
2025-07-29INSM-23.550.905.22
2025-07-30INSM-23.550.905.22
2025-07-31INSM-23.550.905.22
2025-08-01INSM-22.270.905.22
2025-08-04INSM-22.270.615.21
2025-08-05INSM-23.160.615.21
2025-08-06INSM-23.010.615.21
2025-08-07INSM-23.010.615.21
2025-08-08INSM-19.320.615.21
2025-08-11INSM-17.700.565.21
2025-08-12INSM-17.700.560
2025-08-13INSM-16.460.564.61
2025-08-14INSM-16.040.564.61
2025-08-15INSM-16.200.564.61
2025-08-18INSM-16.361.204.61
2025-08-19INSM-16.361.204.61
2025-08-20INSM-15.841.204.61
2025-08-21INSM-15.181.204.61
2025-08-22INSM-15.711.204.61
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.7

Avg. EPS Est. Current Quarter

-1.38

Avg. EPS Est. Next Quarter

-1.2

Insider Transactions

-15.71

Institutional Transactions

1.2

Beta

0.94

Average Sales Estimate Current Quarter

114

Average Sales Estimate Next Quarter

153

Fair Value

Quality Score

38

Growth Score

52

Sentiment Score

92

Actual DrawDown %

0.6

Max Drawdown 5-Year %

-63.3

Target Price

147.82

P/E

Forward P/E

PEG

P/S

70.02

P/B

22.28

P/Free Cash Flow

EPS

-5.7

Average EPS Est. Cur. Y​

-5.51

EPS Next Y. (Est.)

-3.81

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

-259.82

Relative Volume

0.54

Return on Equity vs Sector %

-107.5

Return on Equity vs Industry %

-94.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.32

EBIT Estimation

-50.3
Insmed Incorporated
Sector: Healthcare
Industry: Biotechnology
Employees: 1271
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
stock quote shares INSM – Insmed Incorporated Stock Price stock today
news today INSM – Insmed Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch INSM – Insmed Incorporated yahoo finance google finance
stock history INSM – Insmed Incorporated invest stock market
stock prices INSM premarket after hours
ticker INSM fair value insiders trading